Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cocrystal Pharma Inc (COCP) has issued an update.
Cocrystal Pharma, Inc. has announced progress in the clinical development of their CC-42344 drug candidate, which shows promise as a treatment for both pandemic and seasonal influenza A. The update was shared in a recent press release by the company.
For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.